There is no single EU medical cannabis framework
One of the most important things to understand about European medical cannabis regulation is that it is not harmonised. The European Union does not have a unified cannabis law. Each member state regulates medical cannabis under its own national narcotics legislation, medicines law and clinical guidance — producing a patchwork of more than thirty distinct legal regimes.
The EU does, however, set one universal standard that applies to all cannabis products entering pharmaceutical markets: EU Good Manufacturing Practice. This is the one consistent regulatory thread across all European markets.
The EU GMP requirement for medical cannabis
The European Medicines Agency classifies cannabis as a medicinal product, which means any cannabis product distributed in EU pharmaceutical markets must be produced in an EU GMP certified facility. This applies to all importers, manufacturers and processors in the supply chain — whether the facility is in Portugal, Canada, North Macedonia or Thailand.
EU GMP certification is issued at site level by the national competent authority of the EU member state where the site is located — INFARMED in Portugal, BfArM in Germany, IGJ in the Netherlands. The certificate is recorded in the EMA's EudraGMDP database and is visible to all EU regulators.
Key European markets
Germany is the largest and most accessible European market following the 2024 Cannabis Act, which removed cannabis from the Narcotics Act and allowed any licensed physician to prescribe for any condition. Germany now operates one of the most open prescribing systems in the world and represents the majority of EU import volumes.
The United Kingdom operates independently of EU regulation post-Brexit but accepts EU GMP certification as the quality standard for imports. Portugal is Europe's largest exporter of medical cannabis, supplying Germany, the UK, Poland, Australia and Malta.
France completed its medical cannabis pilot programme in 2024 and integrated cannabis treatment into mainstream medical care. Spain's Royal Decree 903/2025 established a new licensing framework for medical cannabis, with the first post-decree licensees expected in 2026.
What market access requires
For operators seeking to supply European pharmaceutical markets, the practical requirements are consistent across countries: EU GMP certification, appropriate product specifications and analytical data, import and wholesale authorisations from the national competent authority, and a named Qualified Person (QP) responsible for batch certification.
Regulatory affairs strategy varies by market. Germany requires products to meet DAB/DAC pharmacopoeia monographs. The UK requires a separate MHRA import acceptance. France's regulatory pathway is evolving as the pilot data informs permanent policy. Each market requires independent national engagement alongside any EU-level compliance.
References
- Directive 2001/83/EC — Community Code Relating to Medicinal Products for Human Use
- EU GMP Part I and Part II
- EMA Compilation of Community Herbal Monographs and List Entries on Cannabis
- 1961 UN Single Convention on Narcotic Drugs
Confirm the current effective version and national applicability before operational, regulatory or clinical use.
Related content
Regulatory pillarCCPS CertificationEU GMP Certificate GuideMarket Access Checklist